First Time User? Sign Up Now
First Time User? Enroll now.
Home > Health Library > Genetic Test for Clopidogrel
Clopidogrel (Plavix) is a medicine to prevent blood clots, which can cause heart attacks and strokes. It may be prescribed after a heart attack, after angioplasty, and for people who have heart disease or peripheral arterial disease.
Some people have changes, or mutations, to a certain gene (CYP2C19). These changes may keep the body from being able to use clopidogrel to prevent blood clots. If a person with these genetic changes takes clopidogrel, the medicine may not work. This may raise the person's chance of having a heart attack or a stroke.
A genetic test might be used if your doctor thinks that your body is not using clopidogrel properly. This test checks to see if you have genes that let your body use clopidogrel. But experts aren't yet sure whether genetic changes keep clopidogrel from preventing a heart attack or stroke. This genetic test alone is not enough to tell whether the medicine will help you. You also may have a test that shows how your body's platelets are working to clot blood. Having a platelet test after you take an antiplatelet can show if the medicine is working.
The test is done by swabbing the inside of your cheek.
Other Works Consulted
Eikelboom JW, et al. (2012). Antiplatelet drugs: Antithrombotic therapy and prevention of thrombosis, 9th ed.–American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141(2, Suppl): e89S–e119S.
Holmes DR, et al. (2010). ACCF/AHA Clopidogrel clinical alert: Approaches to the FDA "Boxed Warning": A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation, 122(5): 537–557.
Levine GN, et al. (2011). 2011 ACC/AHA/SCAI Guideline for percutaneous coronary intervention: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation, 124(23): e574–e651.
Mega JL, et al. (2010). Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. JAMA, 304(16): 1821–1830.
Paré G, et al. (2010). Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. New England Journal of Medicine, 363(18): 1704–1714.
Current as of: April 9, 2019
Author: Healthwise StaffMedical Review: Rakesh K. Pai MD, FACC - Cardiology, ElectrophysiologyMartin J. Gabica MD - Family MedicineAdam Husney MD - Family Medicine
Current as of:
April 9, 2019
Medical Review:Rakesh K. Pai MD, FACC - Cardiology, Electrophysiology & Martin J. Gabica MD - Family Medicine & Adam Husney MD - Family Medicine
To learn more about Healthwise, visit Healthwise.org.
© 1995-2019 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
131 E. Market St.
Smithfield, NC 27577
1505 SW Cary Parkway
REX Healthcare of Cary, Suite 210
Cary, NC 27511
2076 NC Highway 42 W.
Johnston Professional Plaza, Suite 100
Clayton, NC 27520
781 Avent Ferry Road
REX Healthcare of Holly Springs, Suite 212
Holly Springs, NC 27540
4414 Lake Boone Trail
REX Medical Plaza, Suite 108
Raleigh, NC 27607
UNC REX Healthcare4420 Lake Boone TrailRaleigh, NC 27607, USA919-784-3100
Chosen for Excellence
Co-Worker & Physician Login
UNC Health Talk
Copyright 2020 UNC Health Care. All rights reserved.